![Adrian Field](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Adrian Field
Founder at A.C.N. 142 916 970 Pty Ltd.
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Paul Glyer | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| 7 years |
Bob de Boer | M | - |
A.C.N. 142 916 970 Pty Ltd.
![]() A.C.N. 142 916 970 Pty Ltd. Miscellaneous Commercial ServicesCommercial Services A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia. | 14 years |
Peter Vitins | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Marc Henry Rochat | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Jonathan Moulton | M | 72 |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | - |
Ashley Arthur Woodcock | M | - |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt.
Axalbion SA
| - |
Leigh Mackender | M | - | 16 years | |
Joseph James Caporale | M | - |
A.C.N. 142 916 970 Pty Ltd.
![]() A.C.N. 142 916 970 Pty Ltd. Miscellaneous Commercial ServicesCommercial Services A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia. | 14 years |
Rowan Kennedy | M | - |
A.C.N. 142 916 970 Pty Ltd.
![]() A.C.N. 142 916 970 Pty Ltd. Miscellaneous Commercial ServicesCommercial Services A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia. | - |
Jonathan Field | M | - |
A.C.N. 142 916 970 Pty Ltd.
![]() A.C.N. 142 916 970 Pty Ltd. Miscellaneous Commercial ServicesCommercial Services A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia. | - |
Anton Pirie | M | - | 16 years | |
S. Simon Martin | M | - |
A.C.N. 142 916 970 Pty Ltd.
![]() A.C.N. 142 916 970 Pty Ltd. Miscellaneous Commercial ServicesCommercial Services A.C.N. 142 916 970 Pty Ltd. provides management and operational workforce improvement solutions. It offers end-to-end managed service solution from initial advice on workforce strategy through to implementation of transformation agenda including the ongoing operational management of workforce. The company was founded by Adrian Field, Joe Caporale and Bob de Boer in April 2010 and is headquartered in Melbourne, Australia. | - |
Charles Shortland | M | 33 |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | 8 years |
Spencer Moulton | M | - |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | 10 years |
James Lewis | M | - |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | 5 years |
Candy Ashby | F | - |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | 17 years |
Sara Everett | F | - |
Perscitus Advisers Ltd.
![]() Perscitus Advisers Ltd. Investment ManagersFinance Perscitus Advisers Ltd (Perscitus Advisers) is a private equity firm founded in 2014 by Jon Moulton. The firm is headquartered in London, United Kingdom. | - |
Michael Kitt | M | - |
Axalbion SA
| - |
Michael M. Kitt | M | 73 |
Axalbion Therapeutics Ltd.
![]() Axalbion Therapeutics Ltd. BiotechnologyHealth Technology Axalbion Therapeutics Ltd. has developed a drug candidate for several therapeutic applications. The private company is based in Wythenshawe, UK. The British company has evaluated new patented TRPM8 agonists, which are molecular transducers expressed in sensory neurons. The TRPM8 ion channel is expressed by approximately 10-15% of somatosensory neurons. Axalbion Therapeutics focuses on treating dry eye syndrome (DES), which is a disorder of the tear film due to tear deficiency. The company was founded in 2021, and the CEO is Michael M. Kitt. | - |
Paul Glyer | M | 67 |
Axalbion SA
| - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Michael Edward Doery | M | - | 6 years | |
Patrick Flannigan | M | - | 5 years | |
Russell Andrew Small | M | - | 14 years | |
Stephe Peter Wilks | M | - | 10 years | |
Graeme Sumner | M | - | 3 years | |
Maxwell John Findlay | M | 78 | - | |
Rodney Allen Stanton | M | - | 4 years | |
John Llewellyn Davies | M | - | 5 years | |
Greg Kenyon | M | - | - | |
Alistair Legge | M | - | - | |
Stephen Campbell | M | - | 5 years | |
Paul Le Feuvre | M | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
Australia | 19 | 59.38% |
United Kingdom | 11 | 34.38% |
Switzerland | 6 | 18.75% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Adrian Field
- Personal Network